Msd In The Uk
MSD in the UK is Merck Sharp & Dohme (UK) Limited, the British subsidiary of Merck & Co., Inc., supplying prescription medicines, vaccines, biologic therapies, and animal-health products to NHS trusts, Cancer Alliances, and patient organisations through enterprise field sales and pathway-development partnerships.
- Company typePublic
- Founded1891
- HeadquartersLondon, United Kingdom
- Headcount1,001–5,000
- GTM typeB2B
- OfferingHardware or Manufacturing
What Msd In The Uk does
MSD in the UK operates as Merck Sharp & Dohme (UK) Limited, a wholly-owned subsidiary of Merck & Co., Inc. (NYSE: MRK, headquartered in Rahway, NJ). The UK entity develops, supplies, and markets prescription medicines, vaccines, and biologic therapies across oncology, infectious diseases, cardiovascular, immunology, and endocrinology, alongside a separate MSD Animal Health UK division covering veterinary pharmaceuticals. Go-to-market is enterprise field sales directed at NHS trusts, Cancer Alliances, Clinical Commissioning Groups, and primary-care networks, supplemented by community pharmacy distribution for prescription products and veterinary channels for animal health.
The company's commercial engine is NHS pathway development: collaborative working arrangements with named trusts such as The Christie, Oxford University Hospitals, Bradford Teaching Hospitals, The Clatterbridge Cancer Centre, NHS Lothian, and NHS Tayside have produced measurable outcomes in breast, lung, bladder, ovarian, endometrial, renal, head & neck, and triple-negative breast cancer pathways. A parallel grants programme (18 projects in 2025) and patient-organisation partnerships (Body & Soul, Orchid, Roy Castle Lung Cancer Foundation, The Eve Appeal) extend reach into health-equity, awareness, and community-care segments. Technology stack includes MSD Research Labs (MRL) AI agent infrastructure at the London Bioscience Innovation Centre (King's Cross), the NextGen MDT digital solution co-developed with Axana for lung-cancer multidisciplinary team meetings, and an AI receptionist tool deployed with the North Central London Cancer Alliance that delivered a 160% uplift in cervical-screening bookings.
Revenue mechanics are anchored on prescription pharmaceutical and vaccine sales reimbursed through NHS commissioning frameworks, supplemented by animal-health wholesale and non-revenue philanthropic grant flows to patient organisations. Pricing is not publicly disclosed; commercial value is negotiated trust-by-trust via joint-working and pathway-development agreements rather than via transparent list prices. Strategic posture in 2025 is decisively offensive: the announced ~$10 billion acquisition of UK respiratory biopharma Verona Pharma materially extends the cardio-pulmonary pipeline, while MRL investment, AI-mediated care products, and talent programmes (Top Employer UK/Europe for seven consecutive years; 21,500 global EBRG participants across ten groups) signal sustained reinvestment into differentiated capability rather than defensive restructuring.
Msd In The Uk firmographics
Firmographics- Name
- Msd In The Uk
- Legal name
- Merck Sharp & Dohme (UK) Limited
- Website
- https://msd-uk.com
- Company type
- Public
- Founded year
- 1891
- Operating status
- Operating
- Headcount range
- 1,001–5,000 employees
- Short description
- MSD in the UK is Merck Sharp & Dohme (UK) Limited, the British subsidiary of Merck & Co., Inc., supplying prescription medicines, vaccines, biologic therapies, and animal-health products to NHS trusts, Cancer Alliances, and patient organisations through enterprise field sales and pathway-development partnerships.
- Ownership category
- akta.pro rank
Msd In The Uk industry classification
Industry- Product category
- Pharmaceuticals
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414), Veterinary Services (54194)
- SIC
- Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Vaccine R&D, Clinical/Field Trials & Regulatory Affairs (HLAMAKAM)
- akta.pro secondary industries
- Endocrinology & Metabolic Drugs (e.g., Diabetes, Thyroid) (HLAMAEAG), Veterinary Pharmacy, Vaccine & Biologics Services (AFAEANAK), Veterinary Vaccines (HLAIAEAH)
Keywords
Where Msd In The Uk is headquartered
LocationHeadquarters
- HQ city
- London
- HQ country
- United Kingdom
- HQ region
- Europe
Offices3 records
Markets served
Msd In The Uk business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales
Revenue model
- Prescription Medicines: MSD generates revenue through the sale of prescription medicines for human health, including treatments for oncology, immunology, infectious diseases, and other therapeutic areas.
- Vaccines: MSD develops and sells vaccines for the prevention of diseases.
- Animal Health Products: MSD Animal Health, a division of Merck & Co., Inc., offers veterinary pharmaceuticals, vaccines, and health management solutions for veterinarians, farmers, pet owners, and governments. The division operates in more than 150 countries.
- Grants and Donations: MSD provides arm's length financial grants to eligible healthcare and patient organisations to support projects including educational initiatives, local community support, and advocacy projects. This is a philanthropic programme rather than revenue-generating.
Go-to-market motion1 record
Distribution channels3 records
Marketing channels7 records
Msd In The Uk product offering
Product offeringCore offering
MSD in the UK develops, manufactures, and supplies prescription medicines, vaccines, and biologic therapies for human health across therapeutic areas including oncology, infectious diseases, cardiovascular, and endocrinology. The company also offers veterinary pharmaceuticals and animal health management solutions through its MSD Animal Health division operating in over 150 countries.
Product overview
MSD in the UK is a global healthcare company operating as a trading name of Merck & Co., Inc. The company delivers innovative health solutions through its core products: prescription medicines, vaccines, and biologic therapies. A key division is MSD Animal Health, offering veterinary pharmaceuticals and vaccines. Beyond pharmaceutical products, MSD operates patient-focused initiatives including MSD for Mothers (maternal health), the Defend Your Tomorrow cervical cancer awareness campaign, patient engagement programmes, and grant funding for healthcare and patient organisations. The company also maintains collaborative working partnerships with NHS organisations for pathway development in oncology and vaccines. The portfolio functions as an integrated healthcare ecosystem combining pharmaceutical products with patient support, awareness campaigns, and NHS partnerships to improve health outcomes.
Differentiator
Problem solved
Functional benefit
Brands
- MSD Animal Health: Global animal health business unit offering veterinary pharmaceuticals, vaccines, and health management solutions
- Defend Your Tomorrow
- MSD for Mothers
- MSD UK Grants Programme
- Red Chair Initiative
Products and services
- Prescription Medicines Innovative prescription medicines targeting challenging human diseases across therapeutic areas including oncology, immunology, and infectious diseases, supplied to NHS trusts, hospitals, and healthcare organisations across the UK.
- Vaccines Vaccine products developed for the prevention of diseases, distributed globally through NHS commissioning frameworks, community pharmacies, and public health programmes.
- Biologic Therapies Biologic therapies offered as part of MSD's innovative health solutions portfolio for human health, targeting complex disease areas.
- MSD Animal Health Products Veterinary pharmaceuticals, vaccines, and health management solutions offered to veterinarians, farmers, pet owners, and governments, operating in more than 150 countries.
Quantifiable outcome
- 160% increase in cervical screening booking rate through AI receptionist tool partnership
- +6 more outcomes
Companies that use Msd In The Uk
Customer profileNamed customers12 records
Segments5 records
Ideal customer profiles3 records
Msd In The Uk technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability6 records
Feature2 records
Msd In The Uk partnerships and signals
Strategic signalPartnerships
16 partnerships are on record, tiered core and minor.
- White Ribbon AlliancecoreUK White Ribbon Alliance became an MSD for Mothers Grant Recipient, expanding the Free From Harm training to equip 2,000 maternity care providers to prevent obstetric violence and improve outcomes through trauma-informed, equity-centred care.
- Eli Lilly (embRACE)coreMSD's LEAD UK EBRG collaborates with Eli Lilly's embRACE network to host the annual Health Equity hackathon, bringing together undergraduate students to propose innovative solutions to health equity challenges.
- AxanacoreHealth technology company partnering with MSD and 12 lung cancer clinicians across Europe to develop the NextGen MDT programme - a digital solution to integrate patient information for multidisciplinary team meetings, speeding up lung cancer care.
- Verona PharmacoreUK-based biopharmaceutical company specialising in respiratory diseases that MSD agreed to acquire for approximately $10 billion ($107 per ADS) in July 2025. The acquisition strengthens MSD's innovative pipeline of cardio-pulmonary treatments.
- Arsenal Football ClubcoreMSD partnered with Arsenal FC for the Defend Your Tomorrow® cervical cancer awareness campaign. The partnership leverages Arsenal Women's football team reach to engage communities and individuals across the UK in public health messaging. Activities include matchday takeovers at Emirates Stadium reaching over 55,000 fans.
- The Eve AppealcoreUK gynaecological cancer charity providing advisory services and feedback on campaign content for the Defend Your Tomorrow® campaign. MSD reimburses The Eve Appeal for these services while allowing the charity to maintain independence.
- Body & SoulminorCharity receiving MSD grant funding for Positive Parents Place initiative supporting HIV-positive migrant, asylum-seeker and refugee mothers with workshops, therapies, and advocacy initiatives. Over 228 mothers benefited.
- OrchidminorCharity receiving MSD funding for targeted awareness campaign on testicular cancer, reaching over 880,000 people through engaging social media content and promoting early detection.
- Positive EastcoreEast London-based charity dedicated to supporting people living with and affected by HIV. MSD UK Rainbow Alliance EBRG volunteers support Positive East's RED RUN event and community initiatives.
- Roy Castle Lung Cancer FoundationcorePartnership with Roy Castle Lung Cancer Foundation to develop support materials for lung cancer carers, including the 'How can I support my loved one with Lung Cancer?' booklet providing insights from patient and carer volunteers.
- North Central London Cancer AlliancecorePartnership integrating an AI receptionist tool for cervical screening, resulting in 160% increase in booking rates and administrative time savings, earning national recognition for digital excellence.
- NHS Trusts and Cancer AlliancescoreMSD collaborates with multiple NHS trusts and Cancer Alliances on Pathway Development Programmes and Joint Working arrangements. Partners include Belfast Health and Social Care Trust, Bradford Teaching Hospitals, The Christie NHS Foundation Trust, Oxford University Hospitals, NHS Lothian, The Clatterbridge Cancer Centre, South Yorkshire and Bassetlaw Cancer Alliance, NHS Tayside, and University College London Hospitals.
- Patient Information Forum (PIF)coreMSD is a member of PIF and has achieved the PIF Trusted Information Creator accreditation, demonstrating commitment to accurate and accessible health information.
- Pharmaceutical Supply Chain Initiative (PSCI)coreMSD is a member of PSCI, an industry collaboration supporting principles for responsible supply chain management for ethics, human rights, health and safety, environment, and related governance.
- BSR (Business for Social Responsibility)coreMSD is a member of BSR's Human Rights Working Group, a global cross-industry network focused on human rights challenges and implementing UN Guiding Principles on Business and Human Rights.
- United Nations Global CompactcoreMSD is a signatory to the UN Global Compact, committed to advancing the 10 principles on human rights, labour, environment, and anti-corruption, and the UN Sustainable Development Goals.
Scale indicators10 records
Recent moves6 records
Expansion highlights6 records
Msd In The Uk competitors and assessment
Company assessmentDirect peers
- Pfizer: Global pharmaceutical peer with oncology, vaccines, and biologics portfolios, selling directly into NHS trusts and hospitals across the UK. Operates UK enterprise field sales with comparable pathway partnership models targeting the same prescribers and clinical commissioning groups.
- Bristol-Myers Squibb: Specialty biopharma peer focused on oncology, immunology and cardiovascular therapies with UK field sales. Participates in NHS pathway development (notably in immuno-oncology) and competes directly with MSD's oncology franchise for NHS commissioning share.
- Novartis: Global pharmaceutical peer with prescription medicines spanning oncology, cardiovascular, and immunology therapeutic areas. Operates UK subsidiary selling through enterprise field sales to NHS trusts, comparable therapeutic coverage and similar NHS partnership models.
- Roche: Global pharma peer with heavy oncology and biologic therapy portfolio overlapping MSD's human health pipeline. Sells to NHS trusts through UK field sales and engages in pathway development for cancer care, mirroring MSD's NHS joint-working approach.
- Sanofi: Global pharmaceutical peer with prescription medicines and vaccines, including specialty oncology and immunology products distributed through NHS channels. Operates UK enterprise field sales targeting NHS trusts and Cancer Alliances in a directly comparable model.
- GSK: UK-headquartered peer with strong vaccines, specialty medicines, and HIV portfolios distributed via NHS sales teams. Operates a UK subsidiary with comparable headcount and works on NHS pathway development programmes, directly competing with MSD's oncology and vaccine offerings.
- AstraZeneca: UK-headquartered global pharmaceutical company with comparable oncology, vaccines, and biologics portfolios sold into NHS customers. Like MSD UK, it operates enterprise field sales to NHS trusts, runs joint working partnerships, and lists a UK trading entity with significant employee base.
- Bayer UK: Global pharmaceutical peer with prescription medicines and animal health division (animal health operates in 150+ countries), in both human pharma and veterinary channels comparable to MSD's and MSD Animal Health's dual footprint.
- AbbVie: Specialty biopharma peer with oncology, immunology and biologic therapies targeting NHS prescribers. Operates UK enterprise field sales with comparable pathway development programmes in cancer and chronic disease management.
- Eli Lilly: Global pharmaceutical peer with prescription medicines in oncology, endocrinology, and immunology. Co-hosts the MSD Health Equity Hackathon via the embRACE EBRG, indicating overlapping UK employee engagement and patient access programmes targeting NHS prescribers.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights8 records
Customer concentration
Msd In The Uk social profiles
Digital presenceMsd In The Uk compliance and trust
Trust signalCompliance3 records
Msd In The Uk financial estimates
Financial estimateRevenue estimate
Valuation estimate
Msd In The Uk leadership team
Management profileNumber of profiles
Profiles8 records
Msd In The Uk subsidiaries and ownership
Company hierarchySubsidiaries3 records
Msd In The Uk funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Msd In The Uk M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Msd In The Uk
What does Msd In The Uk do?
MSD in the UK develops, manufactures, and supplies prescription medicines, vaccines, and biologic therapies for human health across therapeutic areas including oncology, infectious diseases, cardiovascular, and endocrinology. The company also offers veterinary pharmaceuticals and animal health management solutions through its MSD Animal Health division operating in over 150 countries.
Is Msd In The Uk a public or private company?
Msd In The Uk is a public company. It is classified as corporate owned and is currently operating.
When was Msd In The Uk founded?
Msd In The Uk was founded in 1891. It employs 1,001 to 5,000 people.
Where is Msd In The Uk based?
Msd In The Uk is headquartered in London, United Kingdom, in the Europe region.
How does Msd In The Uk make money?
Four revenue lines are on record. Prescription Medicines are the primary driver. The others are vaccines, animal Health Products and grants and Donations.
Who are Msd In The Uk's main competitors?
Direct peers on record are Pfizer, Bristol-Myers Squibb, Novartis, Roche, Sanofi, GSK, AstraZeneca, Bayer UK, AbbVie and Eli Lilly.
Does Msd In The Uk have an API?
No public API is recorded for Msd In The Uk.
What industry is Msd In The Uk in?
Msd In The Uk's product category is Pharmaceuticals. Its primary akta.pro industry code is HLAMAKAM, Vaccine R&D, Clinical/Field Trials & Regulatory Affairs, with a secondary code of HLAMAEAG, Endocrinology & Metabolic Drugs (e.g., Diabetes, Thyroid). Its NAICS code is 325412 and its SIC code is 2834.